A novel GFAP frameshift variant identified in a family with optico-retinal dysplasia and vision impairment.

Autor: Sarusie MVK; Department of Clinical Genetics, Kennedy Center, Rigshospitalet, University of Copenhagen, Gamle Landevej 7, 2600 Glostrup, Denmark.; Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark., Rönnbäck C; Department of Ophthalmology, Rigshospitalet-Glostrup, University of Copenhagen, Valdemar Hansens Vej 13, 2600 Glostrup, Denmark., Jespersgaard C; Department of Clinical Genetics, Kennedy Center, Rigshospitalet, University of Copenhagen, Gamle Landevej 7, 2600 Glostrup, Denmark., Baungaard S; Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark., Ali Y; Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark., Kessel L; Department of Ophthalmology, Rigshospitalet-Glostrup, University of Copenhagen, Valdemar Hansens Vej 13, 2600 Glostrup, Denmark.; Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark., Christensen ST; Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark., Brøndum-Nielsen K; Department of Clinical Genetics, Kennedy Center, Rigshospitalet, University of Copenhagen, Gamle Landevej 7, 2600 Glostrup, Denmark., Møllgård K; Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark., Rosenberg T; Department of Ophthalmology, Rigshospitalet-Glostrup, University of Copenhagen, Valdemar Hansens Vej 13, 2600 Glostrup, Denmark., Larsen LA; Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark., Grønskov K; Department of Clinical Genetics, Kennedy Center, Rigshospitalet, University of Copenhagen, Gamle Landevej 7, 2600 Glostrup, Denmark.

Publikováno v: Human molecular genetics [Hum Mol Genet] 2024 Dec 06; Vol. 33 (24), pp. 2145-2158.

Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.

Autor: Verma S; Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada., Butler J; Baylor Scott and White Research Institute, Dallas, Texas, USA., Borlaug BA; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA., Davies MJ; Diabetes Research Centre, University of Leicester, Leicester, United Kingdom; NIHR Leicester Biomedical Research Centre, Leicester, United Kingdom., Kitzman DW; Department of Internal Medicine, Sections on Cardiovascular Medicine and Geriatrics and Gerontology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA., Petrie MC; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom., Shah SJ; Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Jensen TJ; Novo Nordisk A/S, Søborg, Denmark., Rasmussen S; Novo Nordisk A/S, Søborg, Denmark., Rönnbäck C; Novo Nordisk A/S, Søborg, Denmark., Merkely B; Heart and Vascular Centre, Semmelweis University, Budapest, Hungary., O'Keefe E; Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA., Kosiborod MN; Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. Electronic address: mkosiborod@saint-lukes.org.

Publikováno v: Journal of the American College of Cardiology [J Am Coll Cardiol] 2024 Oct 22; Vol. 84 (17), pp. 1603-1614. Date of Electronic Publication: 2024 Aug 30.

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.

Autor: Kosiborod MN; Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. Electronic address: mkosiborod@saint-lukes.org., Deanfield J; Institute of Cardiovascular Science, University College London, London, UK., Pratley R; AdventHealth Translational Research Institute, Orlando, FL, USA., Borlaug BA; Mayo Clinic, Rochester, MN, USA., Butler J; Baylor Scott & White Research Institute, Dallas, TX, USA; Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA., Davies MJ; Diabetes Research Centre, University of Leicester, Leicester, UK; National Institute for Health Research Leicester Biomedical Research Centre, Leicester, UK., Emerson SS; Department of Biostatistics, University of Washington, Seattle, WA, USA., Kahn SE; Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA, USA; University of Washington, Seattle, WA, USA., Kitzman DW; Wake Forest University School of Medicine, Winston-Salem, NC, USA., Lingvay I; University of Texas Southwestern Medical Center, Dallas, TX, USA., Mahaffey KW; Stanford Center for Clinical Research, Stanford School of Medicine, Palo Alto, CA, USA., Petrie MC; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK., Plutzky J; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Rasmussen S; Novo Nordisk, Søborg, Denmark., Rönnbäck C; Novo Nordisk, Søborg, Denmark., Shah SJ; Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Verma S; Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, ON, Canada., Weeke PE; Novo Nordisk, Søborg, Denmark., Lincoff AM; Department of Cardiovascular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.

Publikováno v: Lancet (London, England) [Lancet] 2024 Sep 07; Vol. 404 (10456), pp. 949-961. Date of Electronic Publication: 2024 Aug 30.

Radioprotective Agents: Further Results with Amidophosphorothioate and Related Compounds

Autor: Åkerfeldt, S., Rönnbäck, C., Hellström, M., Nelson, A.

Publikováno v: Radiation Research, 1968 Jul 01. 35(1), 61-67.

Externí odkaz: https://www.jstor.org/stable/3572433

The Effect of X-Irradiation on Various Mouse Strains Due to Their Genetic Background: I. Lethality after Acute Irradiation

Autor: Frölén, H., Lüning, K. G., Rönnbäck, C.

Publikováno v: Radiation Research, 1961 Apr 01. 14(4), 381-393.

Externí odkaz: https://www.jstor.org/stable/3570987